Goldstein is an ophthalmologist, having held several senior medical leadership positions with ophthalmology-focused pharmaceutical companies and published extensively in multiple ophthalmology scientific journals.
In his roles CMO, Goldstein will oversee the clinical development of the company's product pipeline.
Prior to joining Ocular Therapeutix, Goldstein served as CMO of Applied Genetic Technologies Corp. (AGCT), a clinical-stage biotechnology company focused on the development of products for the treatment of rare diseases, with a focus on ophthalmology.
Before joining AGTC, he held several positions of increasing responsibility with Eleven Biotherapeutics, including CMO and vice president of clinical research.
Since 2002, Goldstein has served as co-director, cornea and external disease service and assistant professor of ophthalmology at the New England Eye Center and Tufts University School of Medicine.
Previously, he was director of Refractory Surgery Service and Assistant Professor of Ophthalmology at the University of Florida College of Medicine.
Ocular Therapeutix is focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, Dextenza (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins